Navigation Links
RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
Date:1/13/2009

stimated," "anticipated," or similar expressions, or by express or implied discussions regarding potential regulatory filings or marketing approvals for RAD001 or regarding potential future revenues from RAD001. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with RAD001 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that RAD001 will be approved for sale for any oncology indication in any market. Nor can there be any guarantee that RAD001 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding RAD001 could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this pre
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
3. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
4. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
5. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
6. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
7. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 2014  Moberg ( www.moberg.com ) has received ... medical device used for advanced monitoring of neurological ... a product has met European Union requirements for ... The CNS Monitor captures and analyzes ... waves) to support neurological patient care. The monitor,s ...
(Date:9/29/2014)... , Sept. 29, 2014 EU5 Esophagoscopes ... GlobalData,s new report, "EU5 Esophagoscopes & Gastroscopes ... on the EU5 Esophagoscopes & Gastroscopes market. The ... volume (in units) and average prices (in US ... Flexible Non-Video (Fibre) Gastroscopes and Flexible Video Gastroscopes. ...
(Date:9/29/2014)... September 29, 2014 The global ... billion by 2018, recording a CAGR of 8.8% from ... Devices Market - Global Industry Analysis, Size, Share, Trends ... a U.S.-based market intelligence company. The market, ... from an increasing occurrence of cardiovascular diseases, diabetic retinopathy, ...
Breaking Medicine Technology:Moberg CNS Monitor Receives European CE Mark Approval for Advanced Neurological Monitoring 2EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020 2EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020 3Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 2Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 3Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 4
... MedShape Solutions, Inc, a developer of shape memory orthopedic ... Blair and Tom Hills to the Board of Directors effective ... of experience in the healthcare field, including serving as the ... as the Non-executive Chairman of DJO, Inc., (formerly NYSE-listed sports ...
... Inc. (Pink Sheets: SNDY) is pleased to announce that ... demonstrated at the 95th Annual American College of Surgeons ... During the Breast Ductoscopy for the General Surgeon course, ... hands-on skill stations that will provide the core knowledge ...
Cached Medicine Technology:MedShape Solutions, Inc. Appoints Jack Blair and Tom Hills to Board of Directors; Announces Additions to Management Team 2Solos Endoscopy, Inc.'s MammoView(TM) Product Line to be Demonstrated at the 95th Annual American College of Surgeons Clinical Congress 2
(Date:9/30/2014)... (PRWEB) September 30, 2014 Barbara Williamson ... her amazing memoir "An Extraordinary Life: Love, Sex ... β€œthe messiah of sex,” of the highly successful and ... 1960s and early β€˜70s, the couple started what became ... The clothing-optional, alternate-lifestyle Sandstone Retreat was outrageously popular, with ...
(Date:9/30/2014)... In a move that will ... capture and management functions for sponsors, Synergy Research ... (EDC) system. ClinCapture offers advanced out-of-the-box features that ... clinical trial data and avoid errors and duplications. ... the leading clinical research organization in the Russian ...
(Date:9/30/2014)... 2014 Computer Resources of America, ... based in New York City, has been awarded ... to transform, manage, and support the IT environment ... a leading provider of innovative services that enable ... The contract will cover the four NY-metro ...
(Date:9/30/2014)... September 30, 2014 Miraca Life Sciences ... present eight research posters at the annual meeting of ... will hold its Annual Scientific Meeting and Postgraduate Course ... hall, staff from Miraca Life Sciences will be at ... Clinical Case Challenge. , The research posters for ACG ...
(Date:9/30/2014)... Bibliomotion is proud to announce the release of ... Age by Frank Guglielmo and Sudhanshu Palsule ... apply their leadership coaching experience to introduce Social Leadership – ... behaviors that leaders must adopt in order to thrive in ... a review of The Social Leader in Dialogue Reviews. , ...
Breaking Medicine News(10 mins):Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 2Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 3Health News:Synergy Research Group Opts for Clinovo 2Health News:Synergy Research Group Opts for Clinovo 3Health News:CRA Awarded Managed Services Contract for Large NYC Nonprofit 2Health News:Miraca Life Sciences Research Institute to Present Eight GI Pathology Research Studies at Annual Meeting of American College of Gastroenterologists 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 4Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 5Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 6
... Will build upon Research, Care, Advocacy and Education Programs ... YORK, Jan. 29 The Trustees of the Huntington,s ... that Louise Vetter, currently CEO of the American Lung ... Chief Executive Officer, Monday, March 16. In her nine ...
... Mice whose fat cells were allowed to grow larger than fat ... diet, researchers at UT Southwestern Medical Center found in a new ... called collagen VI, which normally surrounds fat cells and limits how ... The findings appear online and in a future edition of ...
... (RA) remains unclear, bioactive proteins known as cytokines, particularly ... a major role in the disease by contributing to ... cytokine, has been thought to be critical for a ... deliver oxygen and nutrients to fetus. A new study ...
... North State Bancorp (OTC,Bulletin Board: NSBC) (the "Company"), ... of $687.6 million as of December 31, 2008,compared to ... an increase,of $140.1 million or 25.6%. , ... December 31, 2008 were $612.7,million and total loans were ...
... babies have complications, without ill effects, study finds , , THURSDAY, ... steroids to babies still in the womb can reduce their ... their growth the way multiple courses can, new research shows. ... of those given a second dose of steroids in utero ...
... Second Annual "For All the Ways You Care" ... of CaregivingWOONSOCKET, R.I., Jan. 29 CVS/pharmacy, the ... annual "For All the Ways You Care" contest ... http://www.newscom.com/cgi-bin/prnh/20090129/NE64371LOGO )CVS/pharmacy invites caregivers and ...
Cached Medicine News:Health News:Louise Vetter joins Huntington's Disease Society of America as new CEO 2Health News:Louise Vetter joins Huntington's Disease Society of America as new CEO 3Health News:UT Southwestern researchers identify protein that may explain 'healthy' obesity 2Health News:Process found to play role in rheumatoid arthritis could lead to new treatment 2Health News:North State Bancorp Reports Profitable 2008 2Health News:North State Bancorp Reports Profitable 2008 3Health News:North State Bancorp Reports Profitable 2008 4Health News:North State Bancorp Reports Profitable 2008 5Health News:North State Bancorp Reports Profitable 2008 6Health News:Additional Steroid Dose May Help Preemies 2Health News:Additional Steroid Dose May Help Preemies 3Health News:CVS/pharmacy Announces National Contest for Stories of Extraordinary Caregiving 2Health News:CVS/pharmacy Announces National Contest for Stories of Extraordinary Caregiving 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: